Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma Europe
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder
To assess the safety and tolerability of long-term treatment with YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005)
Update Il y a 4 ans
A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Which Contained a Platinum Agent
To evaluate the efficacy of YM155 based on objective tumor response rate (CR+PR) in patients with measurable disease based on RECIST criteria
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVEROLIMUS
The primary objective of this study is to compare two immunosuppressive therapy regimens with respect to their influence on estimated Glomerular Filtration Rate (eGFR) at 52 weeks after conversion to ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE BLADDER SYMPTOM STUDY
To assess the efficacy of solifenacin succinate 5mg od plus simplified bladder training compared with solifenacin succinate 5mg od alone at 8 weeks in subjects with overactive bladder symptoms
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A study to investigate how solifenacin fluid is taken up, how long it stays in the body and how effective and safe it is in treating children aged from 6 months to less than 5 years with symptoms of neurogenic detrusor overactivity
To evaluate the long-term efficacy, safety, and pharmacokinetics (PK) of solifenacin succinate suspension after multiple dose administration.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A study in which multiple applications of Qutenza are investigated in patients with nerve pain
To assess the safety of repeated treatments of QUTENZA in subjects with peripheral neuropathic pain.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
Enzalutamide Treatment of Metastatic Castration-Resistant Prostate Cancer Patients after Abiraterone Acetate Tratamiento con enzalutamida del cáncer de próstata progresivo y metastásico resistente a la castración tras acetato de abiraterona
Evaluation of radiographic progression-free survival (rPFS) Evaluar la supervivencia sin progresión radiográfica (SSPr)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability with Warfarin
The primary objective is to investigate the optimal daily dose and dose regimen of YM150 in subjects with NVAF, primarily based on safety and tolerability data.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
This is a short study, performed in different countries, to investigate how well one dose of mirabegron in tablet form is taken up, how long it stays in the body and how well it will be tolerated in children/adolescents aged 5 to less than 18 years with symptoms of neurogenic detrusor overactivity or overactive bladder
To evaluate the pharmacokinetics of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
This clinical study investigates the effect of fidaxomicin in comparison to vancomycin in adult patients with an infection of Clostridium difficile, and are using medicinal products that suppress the immune system
The primary objective of the study is to demonstrate superiority of fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving i...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
Next